KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Gross Profit (2020 - 2025)

Historic Gross Profit for Vir Biotechnology (VIR) over the last 6 years, with Q2 2025 value amounting to $1.2 million.

  • Vir Biotechnology's Gross Profit fell 6020.51% to $1.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.3 million, marking a year-over-year decrease of 7657.51%. This contributed to the annual value of $73.4 million for FY2024, which is 1205.42% down from last year.
  • According to the latest figures from Q2 2025, Vir Biotechnology's Gross Profit is $1.2 million, which was down 6020.51% from $3.0 million recorded in Q1 2025.
  • In the past 5 years, Vir Biotechnology's Gross Profit ranged from a high of $1.1 billion in Q1 2022 and a low of $1.2 million during Q2 2025
  • For the 5-year period, Vir Biotechnology's Gross Profit averaged around $151.8 million, with its median value being $14.3 million (2022).
  • As far as peak fluctuations go, Vir Biotechnology's Gross Profit skyrocketed by 5770921.05% in 2022, and later crashed by 9926.17% in 2023.
  • Quarter analysis of 5 years shows Vir Biotechnology's Gross Profit stood at $755.9 million in 2021, then tumbled by 94.26% to $43.4 million in 2022, then crashed by 63.17% to $16.0 million in 2023, then dropped by 26.89% to $11.7 million in 2024, then tumbled by 89.71% to $1.2 million in 2025.
  • Its Gross Profit stands at $1.2 million for Q2 2025, versus $3.0 million for Q1 2025 and $11.7 million for Q4 2024.